BiotechTube

dasotraline

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Attention Deficit Hyperactivity Disorder (ADHD)

Conditions

Attention Deficit Hyperactivity Disorder (ADHD), Binge-Eating Disorder Disorder

Trial Timeline

May 1, 2016 → Nov 1, 2016

NCT ID
NCT02795637

About dasotraline

dasotraline is a phase 1 stage product being developed by Sumitomo Pharma for Attention Deficit Hyperactivity Disorder (ADHD). The current trial status is completed. This product is registered under clinical trial identifier NCT02795637. Target conditions include Attention Deficit Hyperactivity Disorder (ADHD), Binge-Eating Disorder Disorder.

What happened to similar drugs?

11 of 20 similar drugs in Attention Deficit Hyperactivity Disorder (ADHD) were approved

Approved (11) Terminated (1) Active (9)
✅atomoxetineEli LillyApproved
✅AtomoxetineEli LillyApproved
✅Atomoxetine HydrochlorideEli LillyApproved
🔄AtomoxetineEli LillyPhase 3
✅AtomoxetineEli LillyApproved
✅Atomoxetine hydrochloride + PlaceboEli LillyApproved
🔄CLONICEL (Clonidine HCl sustained release)ShionogiPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT02795637Phase 1Completed
NCT02684279Phase 3Completed
NCT02457819Phase 3Completed
NCT02160262Phase 3Completed

Competing Products

20 competing products in Attention Deficit Hyperactivity Disorder (ADHD)

See all competitors
ProductCompanyStageHype Score
atomoxetineEli LillyApproved
39
Atomoxetine + PlaceboEli LillyPhase 2/3
38
AtomoxetineEli LillyApproved
35
Atomoxetine HydrochlorideEli LillyApproved
43
AtomoxetineEli LillyPhase 3
40
AtomoxetineEli LillyApproved
43
Atomoxetine hydrochloride + PlaceboEli LillyApproved
43
CLONICEL (Clonidine HCl sustained release)ShionogiPhase 3
40
Donepezil hydrochloride + PlaceboEisaiPhase 3
40
LY2216684 + Methylphenidate + Placebo (tablet) + Placebo (capsule)Eli LillyPhase 2/3
38
Atomoxetine + PlaceboEli LillyApproved
43
AtomoxetineEli LillyApproved
43
AtomoxetineEli LillyPre-clinical
26
Atomoxetine HydrochlorideEli LillyApproved
43
Atomoxetine hydrochlorideEli LillyPhase 3
40
Atomoxetine Hydrochloride + PlaceboEli LillyApproved
43
atomoxetineEli LillyPhase 3
40
atomoxetine 0.5 mg/kg/day + placebo + atomoxetine 1.2 mg/kg/day + atomoxetine 1.2-1.4 mg/kg/dayEli LillyPhase 3
40
Atomoxetine HydrochlorideEli LillyApproved
43
Atomoxetine HydrochlorideEli LillyPhase 3
40